Related Experiment Video
Updated: Mar 25, 2026
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Association Between Hypnotics and Glycemic Variability Assessed by Continuous Glucose Monitoring Under Real-Life
Taichi Muramatsu1, Miku Otsuka1, Daisuke Yamamuro1
1Department of Pharmacotherapy, Meiji Pharmaceutical University, Kiyose, Tokyo, Japan, my-pharm.ac.jp.
Background:
Insomnia is common in patients with Type 2 diabetes and can negatively affect glycemic control. However, the effect of hypnotic use on glycemic variability remains unclear. Therefore, we investigated the association between hypnotic use and glycemic variability in patients with Type 2 diabetes.
Methods:
This cross-sectional study enrolled patients with Type 2 diabetes who underwent continuous glucose monitoring (CGM) between June 1, 2017, and February 28, 2022. Patients were classified into six groups based on their insomnia status and hypnotic use: noninsomnia, hypnotic nonusers, benzodiazepine (BZD) users, nonbenzodiazepine (non-BZD) users, orexin receptor antagonist (ORA) users, and melatonin receptor agonist (MRA) users. We used the standard deviation (SD) of glucose, the coefficient of variation (CV) of glucose, and the mean of daily difference (MODD) as indicators of glycemic variability. The independent association between hypnotic use and glycemic variability was assessed using a multiple linear regression model.
Results:
A total of 534 patients were included in the analysis (mean age: 67.7 ± 10.1 years old; mean diabetes duration: 14.5 ± 8.4 years). Thirty-seven patients (6.9%) used hypnotics, including BZD (n = 13), non-BZD (n = 10), ORA (n = 11), and MRA (n = 3). The SD was significantly higher in non-BZD users (53.6 mg/dL, 95% confidence interval [CI]: 42.9-64.3) than in the noninsomnia group (40.5 mg/dL, 95% CI: 39.5-41.5). MODD was also significantly higher in non-BZD users (50.1 mg/dL, 95% CI: 38.0-62.1) than in the noninsomnia group (35.6 mg/dL, 95% CI: 34.5-36.7). In contrast, the CV was not significantly different between non-BZD users and the noninsomnia group. When analyzed separately for different times of the day, the nocturnal CV was significantly higher in non-BZD users than in the noninsomnia group.
Conclusions:
The use of non-BZDs was associated with within-day and between-day glycemic variability measured by CGM in patients with Type 2 diabetes.
More Related Videos
07:22Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes
Published on: March 7, 2025
07:35Author Spotlight: Investigating the Blood Glucose Homeostasis in Murine Brain Using a Cost-Effective Hyperglycemic And Hypoglycemic Clamp Technique
Published on: January 26, 2024
Related Concept Videos
01:15Hypoglycemia and Glucagon
01:22Diabetes Mellitus: Type 2 and Gestational
01:06Oral Hypoglycemic Agents: Glinides
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
01:15Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:22Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...